# Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy

> **NCT06182800** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Xinxiang Medical College** · enrollment: 35 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Adebrelimab Combined with Bevacizumab and Docetaxel

## Key facts

- **NCT ID:** NCT06182800
- **Lead sponsor:** The First Affiliated Hospital of Xinxiang Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12-27
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2023-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06182800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06182800, "Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06182800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*